Despite the reduction in average tumor growth rates with αCTLA-4, i.d. monotherapy, a group of non-responders persisted (Supplemental Figure S1), which may be due to tumor immune escape, or a loss of MHC in the TME, or an already tolerized tdLN that restricted the successful and prolonged activation of T-cells against tAgs. This evidence concerns the gene HLA-C and neoplasm.